Shield Diagnostics announces launch of Target-NG test for antibiotic susceptibility in Neisseria gonorrhoeae

SAN JOSE, Calif.March 13, 2019 /PRNewswire/ — Shield Diagnostics, an Andreessen Horowitz-backed clinical laboratory tackling antibiotic resistance by bringing precision medicine to infectious disease, announced the launch of Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae.

A common sexually transmitted infection, Gonorrhea has quickly become resistant to most major classes of antibiotics and resistance has now been reported in the final class of antibiotics we have left, requiring those patients to be hospitalized and treated with broad spectrum antibiotics in order to be cured. With 820,000 cases of Gonorrhea each year in the US, the CDC has named antibiotic resistant gonorrhea (dubbed “Super Gonorrhea”) a top 3 urgent public health threat.

TL Biolabs (now Shielddx) Announces $4M in Funding Led by Andreessen Horowitz

TL Biolabs’ $15 genomic test provides farmers information on the health, productivity, and fertility of their cows — from early in the animal’s life — so farmers can make management and breeding decisions earlier and more efficiently. The results are provided in software that helps farmers improve production by selecting which calves to keep or sell, and which bulls to breed to which cows.